Skip to content

Treatment of Premature ejaculation (Early ejaculation of semen) with Unani medicine Majoon-e-Ispand

Clinical Validation of Unani Pharmacopoeial Formulation Majoon-e-Ispand Sokhtani in SurÊ»a al-InzÄ?l (Premature Ejaculation)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/02/017820
Enrollment
240
Registered
2019-02-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N539- Unspecified male sexual dysfunction

Interventions

Intervention1: Majoon-e-Ispand Sokhtani: 5gm orally twice daily with water after meals for two weeks Control Intervention1: nil: nil

Sponsors

Central Council for Research in Unani Medicine CCRUM
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: The following criteria will be strictly followed for inclusion of cases in the study: 1. Men in the age group of 21-65 years 2. Men with a PEDT score > 11 3. Men with lifelong /Acquired PE meeting the evidence-based definition proposed by ISSM: LPE ï?§ IELT ï?§ Inability to delay ejaculation ï?§ Related negative personal consequences, such as distress, bother, frustration, and/or the avoidance of sexual intimacy APE ï?§ A clinically significant reduction in IELT, often ï?§ Lacking the ability to delay ejaculation ï?§ Related negative personal consequences as similar with that of LPE

Exclusion criteria

Exclusion criteria: The patients of SurÊ»a al-InzÄ?l (Premature ejaculation) with following conditions will be excluded from the study: 1. Patients with Erectile dysfunction 2. Major psychiatric disorders or cognitive impairments 3. Patients with history of intake of any drug causing sexual dysfunction and affecting psychological status 4. History of addiction (alcohol, drug abuse) 5. Patients with chronic diseases, requiring long term treatment

Design outcomes

Primary

MeasureTime frame
Improvement in sign and symptoms of SurÊ»a al-InzÄ?l (Premature Ejaculation)Timepoint: 2 weeks

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessment.Timepoint: Investigations will be done at baseline and end of treatment

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine

ccrum507@rediffmail.com9213511298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026